According to results from the phase III trial EA6134 / DREAMseq, starting treatment with nivolumab plus ipilimumab and proceeding to dabrafenib plus trametinib if there was disease progression led to superior overall survival when compared with the opposite treatment sequence. Michael Atkins, MD, principal investigator of the DreamSeq trial and deputy director of Georgetown Lombardi Comprehensive Cancer Center, said these "practice changing results may help resolve ongoing questions about when melanoma patients should receive targeted therapies."